{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:00:58Z","timestamp":1778940058259,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,2,1]],"date-time":"2001-02-01T00:00:00Z","timestamp":980985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2001,2]]},"DOI":"10.1023\/a:1005505827545","type":"journal-article","created":{"date-parts":[[2002,12,21]],"date-time":"2002-12-21T17:31:09Z","timestamp":1040491869000},"page":"376-378","source":"Crossref","is-referenced-by-count":23,"title":["CASE REPORT: Myositis, Microvesicular Hepatitis, and Progression to Cirrhosis from Troglitazone Added to Simvastatin"],"prefix":"10.1007","volume":"46","author":[{"given":"Stephen H.","family":"Caldwell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Erickson","family":"Hespenheide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reid W.","family":"von Borstel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"228741_CR1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJM199908123410707","volume":"341","author":"RH Knopp","year":"1999","unstructured":"Knopp RH: Drug treatment of lipid disorders. N Engl J Med 341:498\u2013511, 1999","journal-title":"N Engl J Med"},{"key":"228741_CR2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7326\/0003-4819-129-1-199807010-00009","volume":"129","author":"BA Neuschwander-Tetri","year":"1998","unstructured":"Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM: Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med 129:38\u201341, 1998","journal-title":"Ann Intern Med"},{"key":"228741_CR3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7326\/0003-4819-129-1-199807010-00008","volume":"129","author":"N Gitlin","year":"1998","unstructured":"Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM: Two case of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 129:36\u201338, 1998","journal-title":"Ann Intern Med"},{"key":"228741_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-2007-979023","volume":"29","author":"T Kaneko","year":"1997","unstructured":"Kaneko T: Troglitazone (CS-045): A new diabetic agent. Horm Metab Res 29:203\u2013213, 1997","journal-title":"Horm Metab Res"},{"key":"228741_CR5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archinte.1991.00400010067008","volume":"151","author":"RH Bradford","year":"1991","unstructured":"Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould L, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H: Expanded clinical evaluation of lovastatin (EXCEL) study results. Arch Intern Med 151:43\u201349, 1991","journal-title":"Arch Intern Med"},{"key":"228741_CR6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7326\/0003-4819-132-2-200001180-00015","volume":"132","author":"J Freid","year":"2000","unstructured":"Freid J, Everitt D, Boscia J: Rosiglitazone and hepatic failure. Ann Intern Med 132:164, 2000","journal-title":"Ann Intern Med"},{"key":"228741_CR7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/0003-4819-132-2-200001180-00006","volume":"132","author":"J Al-Salman","year":"2000","unstructured":"Al-Salman J, Arjomand H, Kemp DG, Mittal M: Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 132:121\u2013124, 2000","journal-title":"Ann Intern Med"},{"key":"228741_CR8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.7326\/0003-4819-132-2-200001180-00005","volume":"132","author":"LM Forman","year":"2000","unstructured":"Forman LM, Simmons DA, Diamond RH: Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 132:118\u2013121, 2000","journal-title":"Ann Intern Med"},{"key":"228741_CR9","unstructured":"Physicians Desk Reference, 54th ed. Montvale, New Jersey, Medical Economics Co., 2000, pp 1917\u20131920"},{"key":"228741_CR10","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1056\/NEJM199803263381314","volume":"338","author":"PB Watkins","year":"1998","unstructured":"Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N Engl J Med 338:916\u2013917, 1998","journal-title":"N Engl J Med"},{"key":"228741_CR11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-131-4-199908170-00008","volume":"131","author":"RA DeFronzo","year":"1999","unstructured":"DeFronzo, RA: Pharmacologic therapy for type 2 diabetes. Ann Intern Med 131:281\u2013303, 1999","journal-title":"Ann Intern Med"},{"key":"228741_CR12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7326\/0003-4819-129-1-199807010-00009","volume":"129","author":"BA Neuschwander-Tetri","year":"1998","unstructured":"Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, Brunt EM: Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med 129:38\u201341, 1998","journal-title":"Ann Intern Med"},{"key":"228741_CR13","unstructured":"Menon KVN, Angulo P, Lindor KD: Severe cholestatic hepatitis from troglitazone in a patient with non-alcoholic steatohepatitis and diabetes mellitus (in press)"},{"key":"228741_CR14","unstructured":"Physicians Desk Reference, 54th ed. Montvale, New Jersey, Medical Economics Co., 2000, pp 2278\u20132282"},{"key":"228741_CR15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3810\/pgm.1999.02.560","volume":"105","author":"MD Johnson","year":"1999","unstructured":"Johnson MD, Newkirk G, White JR: Clinically significant drug interactions. Postgrad Med 105:193\u2013222, 1999","journal-title":"Postgrad Med"},{"key":"228741_CR16","doi-asserted-by":"crossref","first-page":"334A","DOI":"10.1016\/S0168-8278(99)80083-X","volume":"30","author":"R Kumashiro","year":"1999","unstructured":"Kumashiro R, Koga Y, Kubota T, Ishii K, Fukuizumi K, Hino T, Ide T, et al: Higher rate for poor metabolizers of cytochrome P-450 2C19 in patients with liver injury by trogliazone- analysis of allelic variations. Hepatology 30:334A, 1999","journal-title":"Hepatology"},{"key":"228741_CR17","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/jcp.46.11.1055","volume":"46","author":"GF Watts","year":"1993","unstructured":"Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baum H, Quinn PJ: Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 46:1055\u20131057, 1993","journal-title":"J Clin Pathol"},{"key":"228741_CR18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00194398","volume":"46","author":"R Laaksonen","year":"1994","unstructured":"Laaksonen R, Ojala J-P, Tikkanen MJ, Himberg J-J: Serum ubiquinone concentration after short-and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 46:313\u2013317, 1994","journal-title":"Eur J Clin Pharmacol"},{"key":"228741_CR19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2125.1996.04178.x","volume":"42","author":"G De Pinieux","year":"1996","unstructured":"De Pinieux G, Chariot P, Ammi-Said M, Louarn F, Lejonc JL, Astier A, Jacotot B, Gherardi R: Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate\/pyruvate ratio. Br J Clin Pharmacol 42:333\u2013337, 1996","journal-title":"Br J Clin Pharmacol"},{"key":"228741_CR20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0002-9343(93)90129-D","volume":"94","author":"P Chariot","year":"1993","unstructured":"Chariot P, Abadia R, Danan C, Charpentier C: Simvastatininduced rhabdomyolysis followed by a MELAS syndrome. Am J Med 94:109, 1993","journal-title":"Am J Med"},{"key":"228741_CR21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0006-2952(97)00229-3","volume":"54","author":"JM Lenhard","year":"1997","unstructured":"Lenhard JM, Kliewer SA, Paulik MA, Plunker KD, Lehmann JM, Weiel JE: Effects of troglitazone and metformin on glucose and lipid metabolism. Biochemical Pharmacology 54:801\u2013808, 1997","journal-title":"Biochemical Pharmacology"},{"key":"228741_CR22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1210\/endo.139.1.5808","volume":"139","author":"A Camirand","year":"1998","unstructured":"Camirand A, Marie V, Rabelo R, Silva JE: Thiazolidinediones stimulate uncoupling protein-2 expression in cell lines representing white and brown adipose tissues and skeletal muscle. Endocrinology 139:428\u2013431, 1998","journal-title":"Endocrinology"},{"key":"228741_CR23","first-page":"528A","volume":"30","author":"SH Caldwell","year":"1999","unstructured":"Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL: Biochemical, histologic, and mitochondrial ultrastructural effects of troglitazone in nonalcoholic steatohepatitis (NASH). Hepatology 30:528A, 1999","journal-title":"Hepatology"},{"key":"228741_CR24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.24.4.265","volume":"24","author":"S Sherlock","year":"1983","unstructured":"Sherlock S: Acute fatty liver of pregnancy and the microvesicular fat diseases. Gut 24:265, 1983","journal-title":"Gut"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005505827545.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1005505827545\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005505827545.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T02:56:27Z","timestamp":1752461787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1005505827545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2]]}},"alternative-id":["228741"],"URL":"https:\/\/doi.org\/10.1023\/a:1005505827545","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2]]}}}